Immutep (ASX: IMM) Delivers Promising IMP761 Results. Could This Become Its Next Major Growth Driver?

A potentially important breakthrough in immune suppression could strengthen the outlook for Immutep Limited (ASX: IMM), following statistically significant clinical results for its experimental autoimmune treatment, IMP761.

The findings provide encouraging evidence that the treatment can suppress targeted immune responses. However, following the setback of its Phase III lung cancer trial earlier this year, the bigger question is whether Immutep can translate this scientific progress into commercial value while managing its funding requirements.

Key Numbers

• 60 healthy volunteers: Enrolled in the ongoing Phase I IMP761 study.
• Seven dose levels: IMP761 was well tolerated across doses ranging from 0.03 mg/kg to 14 mg/kg.
• Four-week dosing interval: Supported by IMP761's pharmacokinetic profile.
• $48.5 million: Cash and term deposits at 30 September 2026.
• $19.1 million: September-quarter operating cash outflow, down from $38.9 million in the preceding quarter.

IMP761 Delivers Encouraging Clinical Evidence

On 9 November 2026, Immutep released positive findings from a late-breaking abstract for the American College of Rheumatology's ACR Convergence 2026, with the poster presentation scheduled for 10 November.

The Phase I study demonstrated statistically significant, exposure-dependent suppression of T-cell-driven immune responses following a single IMP761 infusion.

Greater drug exposure was associated with stronger biological effects, providing evidence that IMP761 can influence immune activity in a controlled clinical setting.

Importantly, no serious or severe adverse events were reported across the seven tested dose levels.

Complementary preclinical research using samples from rheumatoid arthritis patients also demonstrated statistically significant reductions in T-cell activation and proliferation.

These findings strengthen the scientific rationale for targeting LAG-3, an immune-regulating protein involved in controlling excessive T-cell activity.

However, the human clinical results come from healthy volunteers, not patients with autoimmune diseases.

Demonstrating immune suppression is an important milestone, but it does not yet establish effectiveness against rheumatoid arthritis or other autoimmune conditions.

What Stands Out to Us

IMP761's growing importance follows the discontinuation of Immutep's Phase III TACTI-004 lung cancer trial after an interim futility analysis in March 2026.

The setback increased pressure on the company's oncology strategy and highlighted the value of developing an alternative clinical pipeline.

According to Immutep, IMP761 is the only LAG-3 agonist antibody currently undergoing clinical development, potentially providing a differentiated competitive position.

Nevertheless, that advantage remains commercially unproven.

The company's September-quarter operating cash outflow declined substantially, partly reflecting reduced clinical trial activity following TACTI-004.

Immutep subsequently received approximately $2.16 million through a French research and development tax incentive, providing additional non-dilutive funding beyond its September cash balance.

Management expects its funding runway to extend well into the first half of 2028.

However, future trial expenditure could increase as additional clinical programs advance.

With negligible commercial revenue and no approved products, conventional earnings-based valuation measures remain unsuitable. Immutep's valuation depends heavily on clinical outcomes, potential partnerships and future capital requirements.

What the Company Is Doing Now

Immutep is advancing IMP761 alongside its oncology treatment, eftilagimod alfa, known as efti.

The company is redirecting efti development towards selected head and neck cancers and soft tissue sarcoma, with potential new studies targeted for the second half of 2027.

It is also investigating manufacturing differences between the 2,000-litre efti batches used in TACTI-004 and the 200-litre batches used in earlier studies.

Although structural differences have been identified, their role in the trial's unexpected outcome remains unconfirmed.

A new 200-litre manufacturing run has been contracted to support further development.

Insight: Can IMP761 Strengthen Immutep's Commercial Future?

We think IMP761 represents a credible opportunity to diversify Immutep's pipeline following the TACTI-004 disappointment. Its exposure-dependent results provide meaningful evidence of biological activity, while the rheumatoid arthritis laboratory findings strengthen its scientific rationale. However, clinical effectiveness in patients remains unproven, and the company faces substantial development costs before commercialisation becomes realistic. A successful Phase II program or pharmaceutical partnership could materially improve its prospects. Until stronger clinical and commercial evidence emerges, we believe funding discipline and execution remain more important than speculative valuation upside.

What Happens Next?

The next major IMP761 milestone is the multiple ascending dose data expected during the first half of 2027, which should inform dose selection for potential Phase II testing.

Immutep also plans to provide further findings from its TACTI-004 investigation at its annual general meeting on 27 November 2026.

For shareholders, the critical question is whether improving clinical evidence can attract commercial partnerships and support sustainable development before further capital becomes necessary.